Valacyclovir Treatment for Herpes Simplex Dermatitis

Clinical Efficacy Evidence

• Short-course valacyclovir (2 grams twice daily for 1 day) significantly reduces median episode duration to approximately 5.0 days compared to 6.2 days with placebo, in patients with herpes labialis, according to the Journal of Clinical Virology guidelines 1
• The single-day regimen demonstrated a shorter time to return to normal skin (2.9 days vs 4.5 days with placebo, p < 0.001), in adults with cold sores, as recommended by the Journal of Clinical Virology 1
• Early initiation during the prodromal phase is critical—delaying treatment beyond the first 24 hours substantially reduces efficacy, in patients with herpes labialis, as stated in the Journal of Clinical Virology guidelines 1

Administration and Practical Considerations

• No dose adjustment is needed for patients with creatinine clearance ≥30 mL/min, according to Praxis Medical Insights guidelines 2
• The medication should be readily accessible to the patient so they can self-initiate at the first prodromal symptom—any delay reduces effectiveness, in patients with cold sores, as recommended by the Journal of Clinical Virology 1

Common Pitfalls to Avoid

• Daily suppressive therapy (500-1000 mg once daily) should not be prescribed for episodic cold sores unless the patient has frequent recurrences (≥6 per year) and specifically requests suppression rather than episodic treatment, according to Praxis Medical Insights guidelines 2, 4

When to Consider Suppressive Therapy Instead

• If a patient experiences ≥6 cold sore recurrences per year, daily suppressive therapy with valacyclovir 500 mg once daily should be discussed, as recommended by Praxis Medical Insights guidelines 2
• Suppressive therapy reduces recurrence frequency by ≥75% in patients with frequent outbreaks, according to Praxis Medical Insights guidelines 2, 3